Atezolizumab

1:02
Non-clear cell sarcamatoid kidney cancer treatment updates
Rana McKay
4:02
Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancer
Rana McKay
1:00
IMpassion130: Implications
Peter Schmid
2:30
IMpassion130: immunotherapy for TNBC
Peter Schmid
1:47
TNBC: work to be done
Peter Schmid
0:47
Atezolizumab for TNBC
Erika Hamilton
2:57
Immune-checkpoint inhibitors for urothelial cancer
Petros Grivas
3:07
Neoadjuvant atezolizumab in NSCLC
David Kwiatkowski
0:42
Key challanges in NSCLC
David Kwiatkowski
1:31
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC
Martin Reck
2:30
ABACUS updates: positive results for preoperative atezolizumab in bladder cancer
Thomas Powles
0:56
Targeting the tumor vasculature in mesothelioma
Dean Fennell
0:55
The potential of targeted and immune therapies in SCLC
Martin Reck
4:11
Limiting duration of treatment with checkpoint inhibitors: the data
Jeffrey Weber
4:25
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
Thomas Powles
4:00
Upcoming therapies in the metastatic urothelial carcinoma space
Thomas Powles
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals